Binding of a substance called VEGF is important in treating retinal diseases associated with vascular leakage and abnormal vascular growth, such as wet AMD.

Eylea (Aflibercept) is a 115-kD decoy receptor fusion protein comprising the second domain of human VEGF receptor 1 and the third domain of VEGF receptor 2 fused to the Fc domain of human immunoglobulin G1.

Subretinal fluid (black area under retina profile) pre-treatment with Eylea (upper left) is absorbed one month following treatment with Eylea (lower left), woth improved vision.